Experiment 67319

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEmpty organism
CitationGREEN,A: WILLIAMS,G: NEALE,R: HART,V: LESLIE,D: PARSONS,P: MARKS,GC: GAFFNEY,P: BATTISTUTTA,D: FROST,C: LANG,C: RUSSELL,A:. (1999). DAILY SUNSCREEN APPLICATION AND BETACAROTENE SUPPLEMENTATION IN PREVENTION OF BASAL-CELL AND SQUAMOUS-CELL CARCINOMAS OF THE SKIN: A RANDOMIZED CONTROLLED TRIAL.. 354()
Amount utilized
Compound isolated
DiseaseIN A RANDOMIZED TRIAL WITH A 2 BY 2 FACTORIAL DESIGN, INDIVIDUALS WERE ASSIGNED TO FOUR TREATMENT GROUPS; DAILY APPLICATION OF A SUN PROTECTION FACTOR 15-PLUS SUNSCREEN TO THE HEAD, NECK, ARMS, AND HANDS, AND BETACAROTENE SUPPLEMENTATION (30 MG PER DAY); SUNSCREEN PLUS PLACEBO TABLETS; BETACAROTENE ONLY; OR PLACEBO ONLY. THE ENDPOINTS AFTER 4.5 YEARS OF FOLLOW-UP WERE THE INCIDENCE OF BASAL-CELL AND SQUAMOUS-CELL CARCINOMAS BOTH IN TERMS OF PEOPLE TREATED FOR NEWLY DIAGNOSED DISEASE AND IN TERMS OF THE NUMBERS OF TUMOURS THAT OCCURRED. 1383 PARTICIPANTS UNDERWENT FULL SKIN EXAMINATION BY A DERMATOLOGIST IN THE FOLLOW-UP PERIOD. 250 OF THEM DEVELOPED 758 NEW SKIN CANCERS DURING THE FOLLOW-UP PERIOD. THERE WERE NO SIGNIFICANT DIFFERENCES IN THE INCIDENCE OF FIRST NEW SKIN CANCERS BETWEEN GROUPS RANDOMLY ASSIGNED DAILY SUNSCREEN AND NO DAILY SUNSCREEN. SIMILARLY, THERE WAS NO SIGNIFICANT DIFFERENCE BETWEEN THE BETACAROTENE AND PLACEBO GROUPS IN INCIDENCE OF EITHER CANCER. IN TERMS OF THE NUMBER OF TUMOURS, THERE WAS NO EFFECT ON INCIDENCE OF BASAL-CELL CARCINOMA BY SUNSCREEN USE OR BY BETACAROTENE.
Dose amount30.0 MG
Number1
Qualitative resultINACTIVE
AnimalHUMAN ADULT
Per unitDAY
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES